2024 Annual Meeting | C60 - Clinical Pearls in Autoimmune Neurology: Real-world Cases

Date Sunday 04/14/24

Time 03:30 PM - 05:30 PM MDT Add To Calendar

Session Format This program will be presented both in-person and online

On Demand This program will be available in the meeting's On Demand product.

Event Type Seminar

Director(s) Sarosh R. Irani, MD, PhD, FRCP, FEAN

Topic(s) Autoimmune Neurology

Learning Objectives Participants should be able to recognize and become familiar with case-based descriptions of some of neurology's most treatable autoimmune conditions, spanning the breadth of demyelination, encephalitis, and peripheral neuropathies; recall and interpret investigation features which lead to, and divert from, an accurate autoimmune diagnosis including conditions with antibodies against AQP4, MOG, NMDAR, LGI1, CASPR2, Iglon5, Contactin-1 and NF-155.; and formulate and appraise management plans for these patients.

CME Available 2.00 CME credits

Core Competencies Professionalism, Medical Knowledge, Practice-based Learning and Improvement, Quality Improvement

Program Level Intermediate

Program Tracks Neurohospitalist

Recommended Audience Fellow, Resident, General Neurologist, Specialist Neurologist, Neurohospitalist, Medical Student

Teaching Styles Case-based, Didactic, Audience Participation

Program Evaluations

Event Timeline
03:30 PM - 04:10 PM MDT	Speaker	Treatable Causes of Seizures, Encephalitis, and Movement Disorders Sarosh R. Irani, MD, PhD, FRCP, FEAN
04:10 PM - 04:50 PM MDT	Speaker	Pitfalls and Pearls in Diagnosing Treatable Forms of Demyelination Brian G. Weinshenker, MD, FAAN
04:50 PM - 05:30 PM MDT	Speaker	Treating the Nerve, Muscle and its Junction: Case-based Discussions Christopher Lamb, MD

Faculty Disclosures
Brian G. Weinshenker, MD, FAAN	Dr. Weinshenker has received personal compensation in the range of $500-$4,999 for serving as a Consultant for CANbridge Pharmaceuticals. Dr. Weinshenker has received personal compensation in the range of $0-$499 for serving as a Consultant for CALIBR. Dr. Weinshenker has received personal compensation in the range of $5,000-$9,999 for serving as a Consultant for Horizon. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Alexion. Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche Group (Chugai, Genentech, Roche). Dr. Weinshenker has received personal compensation in the range of $10,000-$49,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB Pharmaceuticals. Dr. Weinshenker has received research support from Guthy Jackson Charitable Foundation. Dr. Weinshenker has received intellectual property interests from a discovery or technology relating to health care.
Sarosh R. Irani, MD, PhD, FRCP, FEAN	Dr. Irani has received personal compensation in the range of $50,000-$99,999 for serving as a Consultant for UCB, Immunovant, MedImmun, Roche, Janssen, Cerebral therapeutics, Biogen, Amgen, Argenex, Clarivate, IQVIA, BioHaven therapeutics, ADC therapeutics, Brain, CSL Behring, and ONO Pharma.. Dr. Irani has received personal compensation in the range of $5,000-$9,999 for serving on a Scientific Advisory or Data Safety Monitoring board for UCB. Dr. Irani has received personal compensation in the range of $500-$4,999 for serving on a Scientific Advisory or Data Safety Monitoring board for Roche. Dr. Irani has received personal compensation in the range of $500-$4,999 for serving as an Editor, Associate Editor, or Editorial Advisory Board Member for Brain. Dr. Irani has received personal compensation in the range of $100,000-$499,999 for serving as an Expert Witness for LLPs. Dr. Irani has received intellectual property interests from a discovery or technology relating to health care. Dr. Irani has received intellectual property interests from a discovery or technology relating to health care. Dr. Irani has received intellectual property interests from a discovery or technology relating to health care.
Christopher Lamb, MD	Dr. Lamb has received research support from Immunovant, Inc.

��ɫ��

��ɫ��